



OncoBioPharm appoints leading cancer development expert Dr Clare Wareing to its Scientific Advisory Board.

Edinburgh, Scotland. 15th March 2016.

OncoBioPharm Limited, an innovative Scottish biotechnology company working in the field of novel cancer therapies, today announced the appointment of Dr Clare Wareing to its Scientific Advisory Board.

Clare is a research specialist in oncology, and she was Founder and CEO of Edinburgh-based oncology drug development experts, Nexus Oncology.

OncoBioPharm's Managing Director Dr Tina Flatau said 'As a leading clinical development specialist in our field, we are lucky to have Clare Wareing join our Scientific Advisory Board. Her experience in effective clinical investigation approaches will be invaluable as we progress our lead antibody candidate, Tensinomab®.'

OncoBioPharm's Chairman, oncology specialist Professor Chris Wood, commented 'Dr Wareing understands the complexities of developing cancer therapeutics and brings a wealth of real experience to our advisory board. We shall benefit from her input as we develop Tensinomab® from our Edinburgh headquarters.'

About OncoBioPharm

OncoBioPharm Ltd is a biotechnology company based in Scotland, developing therapeutic antibodies that target novel pathways associated with cancer cell growth and metastasis. These new targets provide OncoBioPharm with the potential to develop new powerful anti-cancer agents, with a focus on extending and improving the lives of people with cancer.

About Tensinomab

Tensinomab is an antibody that specifically targets the N-terminus of the angiotensin II Type 1 (AT1) receptor. Many major cancers over-express the AT1 receptor, which is associated with cancer cell proliferation, tumour invasion and metastasis. Tensinomab has been shown to block cell growth, invasion and metastasis in a variety of tumour models.